Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach

Medical Decision Making

Volumn 28, Issue 3, 2008, Pages 323-331

  Etzioni, Ruth ^a   Gulati, Roman ^a   Falcon, Seth ^a   Penson, David F ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Computer simulation; Prostate specific antigen; Prostatic neoplasms; Public health

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER TEST; HISTORY; INFORMATION PROCESSING; MEDICAL PRACTICE; PROSTATE CANCER; SENSITIVITY ANALYSIS; SIMULATION; TUMOR BIOPSY; UNITED STATES;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMPUTER SIMULATION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PUBLIC HEALTH; UNITED STATES;

EID: 44049096242     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X07312719     Document Type: Article

References (27)

1. National Cancer Institute. Surveillance, Epidemiology, and End Results registry. Available from: http://seer.cancer.gov/.
2. Barry MJ Revisiting my personal decision about prostatespecific antigen testing in 2005. BJU Int. 2005 ; 96 (7). 954-6.
3. Martin RM, Smith GD, Donovan J. Does current evidence justify prostate cancer screening in Europe ? Nat Clin Pract Oncol. 2005 ; 2 (11). 538-9.
4. Albertsen PC What is the value of screening for prostate cancer in the US ? Nat Clin Pract Oncol. 2005 ; 2 (11). 536-7.
5. Etzioni R., Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF Cancer surveillance series: interpreting trends in prostate cancer-part III: quantifying the link between population prostatespecific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999 ; 91 (12). 1033-9.
6. Lu-Yao G., Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002 ; 325 (7367). 740.
7. Shaw PA, Etzioni R., Zeliadt SB, Mariotto A., Karnofski K., Penson DF, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004 ; 160 (11). 1059-69.
8. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S-O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005 ; 352 (19). 1977-84.
9. Bolla M., Collette L., Blank L., Warde P., Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002 ; 360 (9327). 103-6.
10. Feuer EJ, Mariotto A., Merrill R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer. 2002 ; 95 (4). 870-80.
11. Etzioni R., Cha R., Cowen ME Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol. 1999 ; 162: 741-8.
12. Etzioni R., Cha R., Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998 ; 148 (8). 775-85.
13. Cowen ME, Chartrand M., Weitzel WF A Markov model of the natural history of prostate cancer. J Clin Epidemiol. 1994 ; 47 (1). 3-21.
14. Telesca D., Etzioni R., Gulati R. Estimating lead time and over-diagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (OnlineEarly Articles): doi:10.1111/ j.1541-0420.2007.00825.x.
15. Statistical Research and Applications Branch, Division of Cancer Control and Population Sciences, National Cancer Institute. DevCan-probability of developing or dying of cancer. Available from: http://srab.cancer.gov/devcan/.
16. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. JAMA. 1993 ; 270 (7). 860-64.
17. Inoue L., Etzioni R., Slate E., Morrell C. Combining longitudinal studies of PSA. Biostatistics. 2004 ; 5 (3). 484-500.
18. Etzioni RD, Howlader N., Shaw PA, Ankerst DP, Penson DF, Goodman PJ, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. J Urol. 2005 ; 174 (3). 877-81.
19. Mariotto A., Etzioni R., Krapcho M., Feuer EJ Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007 ; 109 (9). 1877-86.
20. SEER-Medicare Linked Database. Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Available from: http://healthservices.cancer.gov/seermedicare/.
21. Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Urol. 2005 ; 173 (3). 746-50 ; discussion 750-1.
22. Babaian RJ, Toi A., Kamoi K., Troncoso P., Sweet J., Evans R., et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000 ; 163 (1). 152-7.
23. Presti JCJ, Chang JJ, Bhargava V., Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol. 2000 ; 163 (1). 163-6 ; discussion 166-7.
24. Draisma G., Boer R., Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003 ; 95 (12). 868-78.
25. Gann PH, Hennekens CH, Stampfer MJ A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995 ; 273 (4). 289-94.
26. Tsodikov A., Szabo A., Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006 ; 25 (16). 2846-66.
27. Inoue L., Etzioni R., Morrell C., Muller P. Modeling disease progression with longitudinal markers. J Am Stat Assoc. In press.